Skip to content

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
-$65M+72.8%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$4.89M-21.2%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$7.34M-313%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$651K-429%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$12.53M-14.3%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$11M+38.9%

Other financials

Income statement

See full
Revenue$83.1M+38.3%
Gross profit$72.6M+41.2%
Operating income$7.9M+356%
Net income$2.2M+124%
EPS (diluted)$0.01+117%

Balance sheet

See full
Cash & equivalents$111.8M+91.2%
Total debt$258.6M-3.8%
Total equity$13.0M+137%
Total assets$392.0M+24.3%

Cash flow

See full
Operating cash flow$9.9M+198%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.28B+76.9%
Enterprise value$1.42B+52.7%
P/E106.4×
P/S4.1×+0.8×

Profitability

See full
Gross margin85.9%+3.7pp
Operating margin11.4%+7.7pp
Net margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s other income (expense)?
Xeris Biopharma Holdings, Inc. (XERS) reported other income (expense) of -$5.68M in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s other income (expense) changed year-over-year?
Xeris Biopharma Holdings, Inc.'s other income (expense) increased by 7.3% year-over-year, from -$6.13M to -$5.68M.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s other income (expense)?
Over 3 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s other income (expense) has grown at a 47.6% compound annual growth rate (CAGR), from -$7.57M to -$24.34M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.